Syner-G Biopharma Group Announces Karen Casey as Chief People Officer


Syner-G BioPharma Group (Syner-G), a leading provider of integrated pharmaceutical science and regulatory consulting services to the pharmaceutical and medical device industries, today announced that Karen Casey has joined the organization as the chief people officer.

“We are thrilled to welcome Karen Casey into the Syner-G family,” shared Syner-G BioPharma Group CEO, Ron Kraus. “We are a people business and to support our growth, we need an experienced leader to help build and retain a sophisticated workforce as well as build on our culture of excellence.”

”Casey has 27 years’ experience in human resources, operations and talent management spanning a variety of corporate sectors with a track record of building successful human resource functions. Her range of expertise includes building strategic HR functions across HR operations, talent management, and culture aligned with organizational strategy. Casey has a breadth of experience and demonstrated success across large, multinational consumer product companies and start-up organizations where she has created award-winning teams focused on company culture, talent acquisition, talent management and benefit design. She also ran her own consulting firm for 12 years.“

I am excited to join Syner-G as an integral part of the leadership team,” said Karen Casey, chief people officer. “This is an exciting time in the biopharma industry, and I look forward to building from an incredible talent pool and educational environment at Syner-G.”Read more about Karen Casey on LinkedIn here.

About Syner-G BioPharma Group

Based in Boston, MA, Syner-G is a leading provider of customized CMC, regulatory strategy, medical writing, regulatory submissions and publishing services, supporting pharmaceutical and biotechnology companies across the therapeutic spectrum and complete drug development lifecycle. For more information, please visit: https://synergbiopharma.com/

Share article on social media or email:

Leave a Reply